Abstract
Genome-wide association studies have revealed an association between coronary heart disease (CHD) and genetic variation on chromosome 13q34, with the lead single nucleotide polymorphism rs4773144 residing in the COL4A2 gene in this genomic region. We investigated the functional effects of this genetic variant. Analyses of primary cultures of vascular smooth muscle cells (SMCs) and endothelial cells (ECs) from different individuals showed a difference between rs4773144 genotypes in COL4A2 and COL4A1 expression levels, being lowest in the G/G genotype, intermediate in A/G and highest in A/A. Chromatin immunoprecipitation followed by allelic imbalance assays of primary cultures of SMCs and ECs that were of the A/G genotype revealed that the G allele had lower transcriptional activity than the A allele. Electrophoretic mobility shift assays and luciferase reporter gene assays showed that a short DNA sequence encompassing the rs4773144 site interacted with a nuclear protein, with lower efficiency for the G allele, and that the G allele sequence had lower activity in driving reporter gene expression. Analyses of cultured SMCs from different individuals demonstrated that cells of the G/G genotype had higher apoptosis rates. Immunohistochemical and histological examinations of ex vivo atherosclerotic coronary arteries from different individuals disclosed that atherosclerotic plaques with the G/G genotype had lower collagen IV abundance and thinner fibrous cap, a hallmark of unstable, rupture-prone plaques. A study of a cohort of patients with angiographically documented coronary artery disease showed that patients of the G/G genotype had higher rates of myocardial infarction, a phenotype often caused by plaque rupture. These results indicate that the CHD-related genetic variant at the COL4A2 locus affects COL4A2/COL4A1 expression, SMC survival, and atherosclerotic plaque stability, providing a mechanistic explanation for the association between the genetic variant and CHD risk.
Author Summary
People who carry certain variants in their DNA are genetically predisposed to suffer from coronary heart disease (CHD) caused by abnormal tissue buildup (known as atherosclerosis) and blood clotting in the blood vessels of the heart. One of the DNA variants reported to increase CHD risk is named single nucleotide polymorphism rs4773144. It is still unclear as to why this DNA variant has an effect on CHD risk. In this study, by studying blood vessel cells from many people, we found that the DNA variant affects the production of two collagen genes and vascular cell survival. By examining atherosclerotic tissues from many patients, we discovered that the atherosclerotic tissues of patients who carry the rs4773144 variant are structurally more likely to break down and cause blood clotting which can lead to a heart attack. Furthermore, by studying a group of CHD patients, we noticed that those who carry the rs4773144 variant do have higher rates of heart attack. These findings are useful for understanding why this DNA variant has an impact on CHD risk and suggest that preserving adequate production of these two collagen genes may reduce the risk of heart attack in CHD patients, a potential strategy for development of therapeutics for the disease.
Introduction
Coronary heart disease (CHD) is a multifactorial disorder caused by both genetic and life-style factors. Genome-wide association studies (GWASs) have revealed a relationship between the disease and genetic variation on chromosome 13q34 [1, 2]. The lead CHD-associated single-nucleotide-polymorphism (SNP) in this genomic region was rs4773144 located in the third intron of the COL4A2 gene, with the G allele of this SNP associating with increased CHD risk [1, 2]. The molecular and cellular mechanisms underlying this genetic association have, however, remained unclear. Further investigations into such mechanisms are required.
The COL4A1 and COL4A2 genes reside next to each other in the head-to-head orientation on chromosome 13q34 and share common transcriptional regulatory sequences [3–9]. These two genes encode the collagen IV protein α1 and α2 chains, respectively [3–9]. Collagen IV is the major constituent of the basement membrane and is essential for its integrity and functionality [10]. In the blood vessel wall, the basement membrane underlies the endothelium and surrounds smooth muscle cells (SMCs) [11]. The basement membrane not only serves as an extracellular scaffold but also regulates cell behavior [10, 12]. Abnormalities of vascular endothelial cells (ECs) and SMCs play important roles in the pathogenesis of atherosclerosis, the vascular pathology underlying CHD [13].
In this study, we sought to investigate the functional effects of the CHD-associated SNP rs4773144 and found that it has an impact on COL4A2/COL4A1 expression, vascular SMC survival, and coronary atherosclerotic plaque stability.
Results and Discussion
Effect of SNP rs4773144 genotype on COL4A2 and COL4A1 expression
To investigate if SNP rs4773144 genotype had an effect on COL4A2 and COL4A1 expression, we carried out quantitative RT-PCR assays using total RNA samples extracted from primary cultures of vascular SMCs and ECs from different individuals (n = 148 and n = 137, respectively). The assays showed a genotypic effect of rs4773144 on COL4A2 RNA levels in both cell types, with the G allele associating with lower expression level in an additive fashion (Fig 1A and 1B), and a similar effect on COL4A1 RNA levels (Fig 1C and 1D).
The above results suggest that rs4773144 per se, or a SNP in linkage disequilibrium with it, influences COL4A2 and COL4A1 expression. The COL4A1 and COL4A2 genes, situated on chromosome 13q34, are in a head-to-head arrangement, being separated by a bidirectional promoter that drives the transcription of COL4A1 and COL4A2 in opposite directions [3–6]. Studies have shown that transcription of these two genes is modulated by regulatory sequences located in the first intron of each gene and the third intron of COL4A2 [5, 7–9]. SNP rs4773144 resides in the third intron of COL4A2, and is in strong linkage disequilibrium (r2>0.8) with 3 other SNPs (rs4773143, rs7986871 and rs3809346) which are also located in intron 3 of COL4A2. A bioinformatics analysis showed that these SNPs reside in a genomic region that has important transcriptional regulatory features including H3k27Ac marks and DNase I hypersensitivity, identified by the ENCODE and Roadmap Epigenomics project (S1 Fig and S2 Fig).
Therefore, we investigated whether SNP rs4773144 affects gene transcription. To this end, we carried out chromatin immunoprecipitation to capture transcriptionally active chromatins using an antibody against RNA polymerase II (Pol II) and then performed allelic imbalance analyses of the immunoprecipitated chromatins from cells that were heterozygous for rs4773144. The analyses showed that in both SMCs and ECs, the ratio of the rs4773144 G allele versus the A allele was lower in chromatin samples precipitated by the anti-Pol II antibody than in non-precipitated chromatin samples (Fig 2A and 2B), indicating that the G allele has lower transcriptional activity than the A allele. An analogous analysis using an anti-H3k27Ac antibody showed a similar trend (S3 Fig).
To further test if the DNA sequence at the rs4773144 site can modulate gene transcription, we performed a luciferase reporter gene assay. In this experiment, SMCs were transfected with a firefly luciferase gene plasmid containing either the rs4773144 G or A allele sequence as well as a renilla luciferase gene plasmid to serve as a transfection efficiency reference. The experiment showed that G allele plasmid transfectants had lower firefly luciferase levels than A allele plasmid transfectants (Fig 3A), suggesting that the G allele sequence had lower activity in driving gene transcription.
Further experiments using the electrophoretic mobility shift assay technique showed binding of a nuclear protein to oligonucleotide probes corresponding to the DNA sequence at the rs4773144 site, with lower binding efficiency for the G allele [the DNA-protein complex band had a higher intensity in assays with labeled A allele probe (lane 2) than in assays with labeled G allele probe (lane 9), and was reduced more readily by unlabeled A allele probe (lane 4) than by unlabeled G allele probe (lane 6)](Fig 3B). A bioinformatics analysis showed that the DNA sequence at the rs4773144 site (TTCACGGGA[A/G]) shared similarity with the consensus binding element (TTCNNNNGAA) of the transcription factor STAT3 (S4 Fig). To investigate if the protein in the DNA-protein complex mentioned above was STAT3, we performed electrophoretic mobility super-shift assay using an anti-phospho-STAT3 antibody; however, the formation and mobility of the DNA-protein complex mentioned above was unaffected by the antibody (S5 Fig), suggesting that it may involve a different protein.
Effect of SNP rs4773144 genotype on cell behavior
Collagen IV is the major constituent of the basement membrane and participates in cell-matrix and cell-cell communication [14]. Studies have suggested that collagen IV binds to integrins and activates integrin-mediated intracellular signaling, consequently promoting endothelial cell proliferation and inhibiting apoptosis [15–19]. Integrins promote cell survival and inhibit apoptosis, in part by up-regulating the expression of the anti-apoptotic protein BCL2 [20, 21]. In agreement, we found that knockdown of either COL4A2 or COL4A1 in SMCs and ECs resulted in increased apoptosis with a decrease of BCL2 (S6–S9 Figs). Importantly, an analysis of primary cultures of SMCs from different individuals showed an influence of rs4773144 on the rate of apoptosis, with the G allele associating with higher apoptotic rates (Fig 4A). Similarly, there was an association between the G allele and lower levels of the anti-apoptotic protein BCL2 in primary cultures of ECs from different individuals (Fig 4B).
Effect of SNP rs4773144 genotype on collagen IV levels in atherosclerotic plaques and on plaque stability
Further to the assays of primary cultures of vascular cells described above, we investigated if there was a relationship between rs4773144 genotype and collagen IV levels in atherosclerotic plaques. In this investigation, atherosclerotic coronary arteries from different individuals were genotyped for rs4773144 and subjected to immunohistochemical analyses using antibodies against COL4A2 and the smooth muscle cell marker SMA (smooth muscle alpha-actin), respectively. The analyses showed a genotypic effect of rs4773144 on the percentages of COL4A2 positive areas in atherosclerotic plaques, with the G allele associating with lower percentages (Fig 5A and 5B).
It is well established that an atherosclerotic plaque typically contains a lipid core covered by a fibrous cap which is primarily composed of SMCs and extracellular matrix proteins [22]. SMC apoptosis can reduce the SMC content and the thickness of the fibrous cap, rendering the plaque prone to rupture, which can trigger thrombosis [23, 24]. Coronary thrombosis is the most common cause of acute coronary ischemic events such as myocardial infarction (MI) [25, 26].
Since our experiments described earlier showed that rs4773144 genotype influenced SMC apoptosis, we investigated whether rs4773144 genotype had an effect on atherosclerotic plaque cap thickness. Histopathological examination of atherosclerotic coronary arteries from individuals of different genotypes for rs4773144 showed a genotypic effect of rs4773144 in plaque cap thickness, with the G allele associating with thinner plaque cap and lower cap/intima ratio (Fig 5C and 5D, S10 Fig and S11 Fig).
Since atherosclerotic plaques with a thin cap are unstable and prone to rupture [23, 24] and coronary atherosclerotic plaque is the primary cause of MI [25, 26], we investigated if there was an association between rs4773144 and MI in CHD patients. We studied a group of patients with angiographically documented coronary disease with >50% luminal stenosis, and observed a genotypic effect of rs4773144, with the G allele associating with higher rates of MI, which remained after adjusting for age, sex, low-density-lipoprotein cholesterol, hypertension, and diabetes mellitus (Table 1).
Table 1. Association between SNP rs4773144 and MI incidence/prevalence in CHD patients.
MI | Non-MI | odds ratio (95% CI), p-value | odds ratio* (95% CI), p-value | |
---|---|---|---|---|
n (%) | n (%) | |||
A/A genotype | 70 (30.8%) | 163 (38.1%) | reference | reference |
A/G genotype | 106 (46.7%) | 206 (48.1%) | 1.20 (0.83–1.73), p = 0.332 | 1.20 (0.82–1.76), p = 0.356 |
G/G genotype | 51 (22.5%) | 59 (13.8%) | 2.01 (1.26–3.21), p = 0.003 | 2.09 (1.28–3.41), p = 0.003 |
frequency | frequency | |||
A allele | 0.54 | 0.62 | reference | |
G allele | 0.46 | 0.38 | 1.39 (1.10–1.75), p = 0.005 |
*adjusted for age, sex, low-density-lipoprotein cholesterol, hypertension, and diabetes mellitus.
MI, myocardial infarction; CI, confidence interval.
Summary
There are several novel findings from this study on the effect of the CHD-associated SNP rs4773144 located in the COL4A2 gene. At the molecular and cellular levels, a genotypic effect on COL4A2 and COL4A1 expression in vascular ECs and SMCs and on cell survival was detected. From the examination of ex vivo coronary atherosclerotic plaques, we found a relationship between the CHD risk genotype and histological features of plaque instability. Furthermore, in the study of patients with angiographically documented CHD, we observed an association between the risk allele and occurrence of MI. These findings provide a mechanistic explanation for the association between CHD risk and genetic variation at the COL4A1/COL4A2 locus.
Each collagen IV molecule is composed of three α chains forming a triple helical structure, with the classic isoform containing two α1(IV) chains and one α2(IV) chain [27]. The COL4A1 and COL4A2 genes, which encode the α1(IV) and α2(IV) chains respectively, reside next to each other on chromosome 13q34 and are transcriptionally co-regulated [3–9]. Severe rare mutations in either COL4A1 or COL4A2 have been reported to cause vascular lesions and hemorrhagic stroke in humans [14, 28–31], suggesting that defects of either α1(IV) or α2(IV) can result in similar vascular phenotypes. In agreement, our study shows that SNP rs4773144 genotype affects the expression of both COL4A1 and COL4A2, and the siRNA experiments demonstrate that knockdown of either COL4A1 or COL4A2 in vascular SMCs or ECs induces cell apoptosis (which is line with a reported finding that a frame shift mutation in the COL4A2 gene increases rates of apoptosis of fibroblasts isolated from an individual carrying the mutation [31]). Apart from providing a mechanistic explanation for the association between rs4773144 and CHD, these results suggest that preserving adequate production of both of these two collagen IV genes can be a potential strategy for developing new therapeutics for the disease.
Data from the ENCODE and Roadmap Epigenomics projects show DNase I hypersensitivity and histone modifications surrounding rs4773144 in a number of different types of cells and tissues including SMCs, ECs, monocytes, T-cells, B-cells, adipose, heart, skeletal muscle, brain, thymus, etc. It is possible that rs4773144 genotype may affect COL4A2/COL4A1 expression not only in vascular SMCs and ECs as demonstrated in this study but also in other cells, and that additional functional mechanisms involving other tissues may also contribute to the association between rs4773144 and CHD.
Over 50 genomic loci have hitherto been identified by GWASs to be associated with CHD risk [32]. However, for many of these loci, the functional mechanisms leading to the genetic effect remain unknown. Functional characterization of these genetic variants can aid the understanding of the underlying biological mechanisms and may facilitate the translation of the genetic discoveries to therapeutic development. The findings of our present study on the CHD-related genetic variant at the COL4A1/COL4A2 locus are pertinent in this context.
Materials and Methods
Ethics statement
NRES Committee London–City & East (approval number: 08/H0704/140) and Shantou University Medical College Ethics Committee approved this research.
Isolation, culture and analyses of primary vascular SMCs and ECs
SMCs were isolated from arteries of umbilical cords from different individuals; ECs were isolated from umbilical cord veins. Isolated SMCs and ECs were subjected to immunocytochemical examinations of the SMC marker SMA, the EC marker von Willebrand factor (vWF), and the fibroblast marker discoidin domain receptor-2 (DDR2), which verified that SMCs were SMA-positive but vWF- and DDR2-negative and that ECs were vWF-positive but SMA- and DDR2-negative. Primary cultures of SMCs and ECs, up to passage 5, were used in experiments of this study.
Determination of genotypes
Genomic DNA was extracted from cultured SMCs and ECs or from sections of formaldehyde-fixed paraffin-embedded blocks of atherosclerotic coronary arteries using the Wizard SV Genomic DNA Purification System (Promega). rs4773144 genotypes were determined with the use of the TaqMan SNP genotyping assay. Accuracy of the genotyping results was verified by sequencing of a random selection of the samples.
Quantitative reverse transcriptase–polymerase chain reaction
Total RNA samples were prepared from primary cultures of SMCs and ECs, with the use of the SV Total RNA Isolation System (Promega). RNA was reverse transcribed into cDNA using random primers (Promega) and M-MLV reverse transcriptase (Promega). The resultant cDNA was subjected to real-time polymerase chain reactions for COL4A1, COL4A2, and β-actin, respectively, with the use of TaqMan Gene Expression Assays. The 2-∆∆CT method [33] was used to ascertain differences between genotypes in COL4A1 and COL4A2 levels standardized against the reference gene β-actin.
Chromatin immunoprecipitation and allelic imbalance assays
SMCs and ECs, heterozygous for SNP rs4773144, were crosslinked by incubation in formaldehyde and then incubated with glycine to quench formaldehyde. Subsequently, cells were lysed and chromatin sheared to 200–1,000bp in length by sonication. Aliquots of the samples were incubated with protein G-agarose beads and then further with an anti-human RNA polymerase II antibody (Santa Cruz Biotechnology, sc-9001). DNA-protein-antibody complexes bound to protein G-agarose beads were precipitated by centrifugation and de-crosslinked. Sheared chromatin samples and immunoprecipitated DNA samples were subjected to allelic imbalance analyses of SNP rs4773144, with the use of the TaqMan method to determine the Ct values for the A allele (detected by a VIC fluorescein-labeled probe) and G allele (detected by a FAM fluorescent dye-labeled probe), respectively. Additionally, heterozygous ECs were subjected to chromatin immunoprecipitation using an anti-human H3k27Ac antibody (Abcam ab4729) and then TaqMan assay to determine the G allele versus A allele ratio.
Luciferase reporter gene assays
A 350 base pair DNA sequence encompassing the rs4773144 site of the A and G alleles, respectively, was amplified by PCR and inserted into the pGL3-promoter vector (Promega) containing a firefly luciferase reporter gene. The resultant construct containing the inserted DNA sequence corresponding to either the A or G allele of rs4773144 was mixed with a plasmid (pRL-TK, Promega) containing a renilla luciferase gene and transfected into cultured vascular SMCs. At 48 hours after transfection, the transfectants were lysed, and the activities of firefly luciferase and renilla luciferase in the lysates were measured. The ratio of firefly luciferase activity to renilla luciferase activity was used as a measurement of the transcription modulating activity of the inserted DNA sequence encompassing the rs4773144 site of the A and G alleles, respectively.
Electrophoretic mobility shift assays
Biotin-labelled, double-stranded 25-mer oligonucleotides corresponding to the sequences at and surrounding the SNP rs4773144 site were used as probes. The probe sequences were: 5'-CCTTTCACGGGAACTGGGAACTTAA-3' (A allele) and 5’-CCTTTCACGGGAGCTGGGAACTTAA-3’ (G allele), respectively. The probes were individually incubated with nuclear extracts of cultured ECs, in the presence or absence of unlabelled oligonucleotide competitors in molar excess or an anti-phospho-STAT3 antibody (Cell Signaling Technology, #9131), followed by non-denaturing polyacrylamide gel electrophoresis. Free probes and probe-protein complexes were detected using a LightShift Chemiluminescent EMSA kit (Pierce Biotechnology, 20148). Three independent experiments were carried out.
COL4A2 or COL4A1 siRNA knockdown
SMCs and ECs were transfected with either COL4A2 siRNA (ThermoFisher Scientific, 4457308), COL4A1 siRNA (ThermoFisher Scientific, AM16708), or control siRNA (ThermoFisher Scientific, 4390843), with the use of Lipofectamine RNAiMAX transfection reagent (Invitrogen, 13778150). COL4A2 or COL4A1 knockdown was verified by immunoblotting analysis.
Immunoblotting analyses
Cell lysates were prepared by incubating cells with a lysis buffer containing a protease inhibitor cocktail. An aliquot of 20μg proteins from each sample was subjected to Tris-glycine, sodium-dodecyl-sulfate, polyacrylamide gel electrophoresis, followed by standard immunoblotting analysis with an anti-COL4A2 antibody (Abcam, ab69782), an anti-COL4A1 antibody (Abnova, PAB17326), an anti-BCL2 antibody (Abcam, ab32124), an anti-β-actin antibody, or an anti-HSC70 antibody (Santa Cruz, sc7298).
Cell accumulation and apoptosis assays
SMCs (same number) or ECs (same number) transfected with either the COL4A2 siRNA, COL4A1 siRNA or control siRNA, or untransfected primary SMCs (same number) from different individuals, were cultured for 72 hours, and then detached and counted. Additionally, cells were subjected to apoptosis assays with the use of Annexin V-FITC apoptosis detection kit (Beyotime Institute of Biotechnology, C1062, for transfected cells) or Cell Death Detection ELISAPLUS kit (Roche, 11774425001, for untransfected cells) to quantify histone-complexed DNA fragments.
Immunohistochemical analysis of ex vivo coronary artery atherosclerotic plaques
Formaldehyde-fixed paraffin-embedded sections of atherosclerotic coronary arteries from autopsies were deparaffinised, rehydrated, and incubated in sodium citrate for antigen retrieval. The sections were subjected to peroxidase immunostaining with a mouse anti-human smooth muscle α-actin (SMA) antibody (Dako, M-0635). A subset of the collection was subjected to peroxidase/alkaline phosphatase double immunostaining with the mouse anti-human smooth muscle α-actin (SMA) antibody (Dako, M-0635) and a rabbit anti-human COL4A2 antibody (Abcam, ab69782). Chromagens were diaminobenzidine and nitrobluetetrazolium/bromo-chloro-indolyl phosphate, respectively. Images of the sections were captured using a microscope with an imaging system and analyzed using Image-Pro software to determine the sizes of positive immunostain areas, atherosclerotic plaque cap thickness, and intima thickness.
Patients with angiographically documented coronary artery disease
We studied 1125 consecutive patients undergoing diagnostic or interventional coronary angiography in the First Affiliated Hospital of Shantou University Medical College. All subjects were Chinese. We collected demographic and clinical data including age, sex, plasma levels of total cholesterol, low-density-lipoprotein cholesterol, high-density lipoprotein cholesterol and triglycerides, coronary angiographic findings, incident or prevalent MI diagnosed according to the World Health Organization criteria, systolic and diastolic blood pressure, and the presence or absence of diabetes mellitus. Of the 1125 subjects, 655 had significant angiographically documented CHD as having >50% diameter stenosis in ≥1 major epicardial coronary artery. Among them, a total of 227 subjects had incident or prevalent MI. The study was approved by the appropriate research ethics committee. The data were analyzed anonymously.
Statistical analyses
Variables not in normal distribution were normalized by logarithmic transformation. Linear regression analyses were performed to test differences between genotypes in COL4A1 and COL4A2 expression levels, apoptosis assay result, BCL2 immunoblotting band intensity (standardized against HSC70 band intensity), percentage of COL4A2 stain areas in total atherosclerotic plaque area, atherosclerotic plaque cap thickness, and atherosclerotic plaque cap/intima ratio, in an additive genetic model. Student’s t-tests were used to ascertain allelic differences in the allelic expression imbalance assays and the chromatin immunoprecipitation assays. Student’s t-tests were also used to test differences between cells transfected with either the rs4773144 A allele plasmid or G allele plasmid in firefly luciferase activity after standardized against renilla luciferase activity in the luciferase assays, and between cells transfected with COL4A2 siRNA or COL4A1 siRNA and cells transfected with control siRNA in cell count, proliferation assay result, apoptosis assay result, and BCL2 immunoblotting band intensity (standardized against β-actin band intensity), respectively. Logistic regression analyses and chi-squared tests were carried out to ascertain genotypic and allelic association with MI in CHD patients. All p values were two-sided.
Supporting Information
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
The study was supported by the British Heart Foundation (PG/16/9/31995) and the National Natural Science Foundation of China (81370202). The work forms part of the research themes contributing to the translational research portfolio of Barts Cardiovascular Biomedical Research Unit supported and funded by the National Institute of Health Research, and falls under the portfolio of research conducted within the National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature genetics. 2011;43(4):333–8. 10.1038/ng.784 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.ARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nature genetics. 2013;45(1):25–33. 10.1038/ng.2480 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Poschl E, Pollner R, Kuhn K. The genes for the alpha 1(IV) and alpha 2(IV) chains of human basement membrane collagen type IV are arranged head-to-head and separated by a bidirectional promoter of unique structure. The EMBO journal. 1988;7(9):2687–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Soininen R, Huotari M, Hostikka SL, Prockop DJ, Tryggvason K. The structural genes for alpha 1 and alpha 2 chains of human type IV collagen are divergently encoded on opposite DNA strands and have an overlapping promoter region. The Journal of biological chemistry. 1988;263(33):17217–20. [PubMed] [Google Scholar]
- 5.Burbelo PD, Martin GR, Yamada Y. Alpha 1(IV) and alpha 2(IV) collagen genes are regulated by a bidirectional promoter and a shared enhancer. Proceedings of the National Academy of Sciences of the United States of America. 1988;85(24):9679–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Heikkila P, Soininen R, Tryggvason K. Directional regulatory activity of cis-acting elements in the bidirectional alpha 1(IV) and alpha 2(IV) collagen gene promoter. The Journal of biological chemistry. 1993;268(33):24677–82. [PubMed] [Google Scholar]
- 7.Fischer G, Schmidt C, Opitz J, Cully Z, Kuhn K, Poschl E. Identification of a novel sequence element in the common promoter region of human collagen type IV genes, involved in the regulation of divergent transcription. The Biochemical journal. 1993;292 (Pt 3):687–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Haniel A, Welge-Lussen U, Kuhn K, Poschl E. Identification and characterization of a novel transcriptional silencer in the human collagen type IV gene COL4A2. The Journal of biological chemistry. 1995;270(19):11209–15. [DOI] [PubMed] [Google Scholar]
- 9.Pollner R, Schmidt C, Fischer G, Kuhn K, Poschl E. Cooperative and competitive interactions of regulatory elements are involved in the control of divergent transcription of human Col4A1 and Col4A2 genes. FEBS letters. 1997;405(1):31–6. [DOI] [PubMed] [Google Scholar]
- 10.Yurchenco PD. Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harbor perspectives in biology. 2011;3(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Katsuda S, Okada Y, Minamoto T, Oda Y, Matsui Y, Nakanishi I. Collagens in human atherosclerosis. Immunohistochemical analysis using collagen type-specific antibodies. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1992;12(4):494–502. [DOI] [PubMed] [Google Scholar]
- 12.Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nature reviews Cancer. 2003;3(6):422–33. [DOI] [PubMed] [Google Scholar]
- 13.Ross R. The pathogenesis of atherosclerosis—an update. The New England journal of medicine. 1986;314(8):488–500. [DOI] [PubMed] [Google Scholar]
- 14.Kuo DS, Labelle-Dumais C, Gould DB. COL4A1 and COL4A2 mutations and disease: insights into pathogenic mechanisms and potential therapeutic targets. Human molecular genetics. 2012;21(R1):R97–110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Kern A, Eble J, Golbik R, Kuhn K. Interaction of type IV collagen with the isolated integrins alpha 1 beta 1 and alpha 2 beta 1. European journal of biochemistry / FEBS. 1993;215(1):151–9. [DOI] [PubMed] [Google Scholar]
- 16.Pedchenko V, Zent R, Hudson BG. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. The Journal of biological chemistry. 2004;279(4):2772–80. [DOI] [PubMed] [Google Scholar]
- 17.Wang H, Su Y. Collagen IV contributes to nitric oxide-induced angiogenesis of lung endothelial cells. American journal of physiology Cell physiology. 2011;300(5):C979–88. 10.1152/ajpcell.00368.2010 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hoyt DG, Mannix RJ, Gerritsen ME, Watkins SC, Lazo JS, Pitt BR. Integrins inhibit LPS-induced DNA strand breakage in cultured lung endothelial cells. The American journal of physiology. 1996;270(4 Pt 1):L689–94. [DOI] [PubMed] [Google Scholar]
- 19.Hoyt DG, Rizzo M, Gerritsen ME, Pitt BR, Lazo JS. Integrin activation protects pulmonary endothelial cells from the genotoxic effects of bleomycin. The American journal of physiology. 1997;273(3 Pt 1):L612–7. [DOI] [PubMed] [Google Scholar]
- 20.Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(13):6161–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Matter ML, Ruoslahti E. A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription. The Journal of biological chemistry. 2001;276(30):27757–63. [DOI] [PubMed] [Google Scholar]
- 22.Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92(5):1355–74. [DOI] [PubMed] [Google Scholar]
- 23.Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. The Journal of clinical investigation. 1995;95(5):2266–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.McCarthy NJ, Bennett MR. The regulation of vascular smooth muscle cell apoptosis. Cardiovascular research. 2000;45(3):747–55. [DOI] [PubMed] [Google Scholar]
- 25.Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91(11):2844–50. [DOI] [PubMed] [Google Scholar]
- 26.Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996;94(8):2013–20. [DOI] [PubMed] [Google Scholar]
- 27.Hudson BG, Reeders ST, Tryggvason K. Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis. The Journal of biological chemistry. 1993;268(35):26033–6. [PubMed] [Google Scholar]
- 28.Gould DB, Phalan FC, Breedveld GJ, van Mil SE, Smith RS, Schimenti JC, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science. 2005;308(5725):1167–71. [DOI] [PubMed] [Google Scholar]
- 29.Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. The New England journal of medicine. 2006;354(14):1489–96. [DOI] [PubMed] [Google Scholar]
- 30.Jeanne M, Labelle-Dumais C, Jorgensen J, Kauffman WB, Mancini GM, Favor J, et al. COL4A2 mutations impair COL4A1 and COL4A2 secretion and cause hemorrhagic stroke. American journal of human genetics. 2012;90(1):91–101. 10.1016/j.ajhg.2011.11.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Verbeek E, Meuwissen ME, Verheijen FW, Govaert PP, Licht DJ, Kuo DS, et al. COL4A2 mutation associated with familial porencephaly and small-vessel disease. Eur J Hum Genet. 2012;20(8):844–51. 10.1038/ejhg.2012.20 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.ARDIoGRAMplusC4D Consortium. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature genetics. 2015;47(10):1121–30. 10.1038/ng.3396 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.